Structure of PLX51107
CAS No.: 1627929-55-8
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
PLX51107 is a potent and selective BRD4 inhibitor or BET inhibitor with novel in vitro and in vivo pharmacologic properties that emulates or exceeds the efficacy of BCR signaling agents in preclinical models of CLL.
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 1627929-55-8 |
Formula : | C26H22N4O3 |
M.W : | 438.48 |
SMILES Code : | O=C(O)C1=CC=C(C2=CN([C@H](C3=NC=CC=C3)C)C4=CC(C5=C(C)ON=C5C)=CN=C42)C=C1 |
MDL No. : | MFCD31657388 |
InChI Key : | AMSUHYUVOVCWTP-INIZCTEOSA-N |
Pubchem ID : | 90448953 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
Target |
|
In Vitro:
Cell Line
|
Concentration | Treated Time | Description | References |
OCI-AML3 | 1 µM | 96 hours | CGM097 showed synergy with AZD6244 in OCI-AML3 cells | PMC10913666 |
OCI-AML3 cells | 250 nM | 3 hours | Evaluate the inhibitory effect of PLX51107 on MYC expression | PMC8017818 |
MOLM-14 cells | 79 nM | Evaluate the inhibitory effect of PLX51107 on FLT3-ITD mutated AML cells | PMC8017818 | |
Primary CLL cells | 1μM | 4 hours | To assess the effect of PLX51107 on BRD4 binding, results showed significant reduction in BRD4 load at enhancer regions | PMC5882533 |
Omm1.3 cells | 0.5 μM | 48 hours | Validate the synergistic effect of PTL with PLX51107, inhibiting NF-κB signaling and inducing apoptosis. | PMC6643281 |
92.1 cells | 0.04-5 μM | 72 hours | Evaluate the combinatorial therapeutic effects of PLX51107 with a compound library, identifying NF-κB inhibitors PTL and PDTC as synergistic with PLX51107. | PMC6643281 |
MOLM-13 | 1 µM | 96 hours | To evaluate the effect of PLX51107 on AML cell viability, results showed that PLX51107 reduced AML cell viability | PMC10913666 |
MV4-11 | 1 µM | 96 hours | To evaluate the effect of PLX51107 on AML cell viability, results showed that PLX51107 reduced AML cell viability | PMC10913666 |
M238 cells | 1, 2 and 4 μM | 24 hours to 3 weeks | PLX51107 combined with BRAFi/MEKi significantly inhibited the growth of M238 cells and reduced S-phase entry. | PMC7078299 |
1205Lu cells | 1, 2 and 4 μM | 24 hours to 3 weeks | PLX51107 combined with BRAFi/MEKi significantly inhibited the growth of 1205Lu cells and reduced S-phase entry. | PMC7078299 |
A375 cells | 1, 2 and 4 μM | 24 hours to 3 weeks | PLX51107 combined with BRAFi/MEKi significantly inhibited the growth of A375 cells and reduced S-phase entry. | PMC7078299 |
MV4-11 cells | 62 nM | Evaluate the inhibitory effect of PLX51107 on FLT3-ITD mutated AML cells | PMC8017818 | |
DLBCL cell lines (SUDHL6, OCI-LY1, OCI-LY8, DOHH2) | 1000 nM | 48 hours | In BCL-2-high DLBCL cell lines, PLX51107 and PLX2853 showed limited efficacy alone but exhibited synergistic effects when combined with the BH3 mimetic ABT199, significantly enhancing apoptosis. | PMC7391160 |
Em-myc lymphoma cell lines | 1000 nM | 48 hours | PLX51107 and PLX2853 induced apoptosis by upregulating BIM protein and suppressing the miR-17~92 cluster, resulting in cytotoxic responses in BCL-2-low MYC-driven lymphomas. | PMC7391160 |
Rheumatoid arthritis patient CD14+ monocytes | 50, 250 nM | 48 hours | To evaluate the effect of PLX51107 on FcγR expression in monocytes from rheumatoid arthritis patients. Results showed that PLX51107 significantly downregulated FcγRIIa, FcγRIIb, FcγRIIIa, and γ chain mRNA expression, while upregulating FcγRIa expression. | PMC10143512 |
Healthy donor CD14+ monocytes | 50, 100, 200, 250 nM | 24 hours | To evaluate the effect of PLX51107 on the transcriptional expression of FcγRIIa, FcγRIIb, FcγRIIIa, and FcεRIγ. Results showed that PLX51107 significantly downregulated FcγRIIa, FcγRIIb, and FcγRIIIa mRNA expression, while upregulating FcγRIa expression. | PMC10143512 |
HBLAK | 0.6 µM | 72 hours | PLX51107 inhibited cell growth, caused DNA damage, and blocked DNA repair response in UC cells | PMC8002916 |
UM-UC-3 | 8.8 µM | 72 hours | PLX51107 inhibited cell growth, caused DNA damage, and blocked DNA repair response in UC cells | PMC8002916 |
VM-CUB1 | 2 µM | 72 hours | PLX51107 inhibited cell growth, caused DNA damage, and blocked DNA repair response in UC cells | PMC8002916 |
THJ-16T cells | 500 nM | 5 days | Evaluate the effect of PLX on cell proliferation, results showed that PLX inhibited the proliferation of THJ-16T cells, reducing cell numbers by 88.4%. | PMC6938575 |
THJ-11T cells | 500 nM | 5 days | Evaluate the effect of PLX on cell proliferation, results showed that PLX inhibited the proliferation of THJ-11T cells, reducing cell numbers by 88.9%. | PMC6938575 |
In Vivo:
Species
|
Animal Model
|
Administration | Dosage | Frequency | Description | References |
Mice | Eμ-TCL1 transgenic mouse model | Oral gavage | 20 mg/kg | Once daily for eight days | To assess the effect of PLX51107 on leukemia burden, results showed significant reduction in leukemic cells in peripheral blood and spleen | PMC5882533 |
Athymic nu/nu mice | R-Omm1.3 xenograft model | Oral and intraperitoneal injection | PLX51107 20 mg/kg orally | Three times a week for 5 weeks | Evaluate the effect of PLX51107 combined with PTL on BETi-resistant tumors, showing significant inhibition of tumor growth. | PMC6643281 |
NSG mice | MOLM-13-luciferase xenograft model | Oral gavage | 20 mg/kg | Daily administration until the end of the experiment | To evaluate the anti-leukemic effect of PLX51107 in vivo, results showed that PLX51107 significantly prolonged the survival of mice | PMC10913666 |
Nude mice | 1205Lu and A375 xenograft models | Oral | 90 ppm | Intermittent dosing (2 days on/5 days off) | Intermittent PLX51107 combined with BRAFi/MEKi treatment significantly delayed tumor recurrence and improved animal survival. | PMC7078299 |
SCID mice | MV4-11 xenograft model | Oral | 10, 20, 40 mg/kg | Once daily for 14 days | Evaluate the anti-tumor effect of PLX51107 as a single agent in FLT3-ITD AML xenograft model | PMC8017818 |
Mice | Em-myc lymphoma model | Oral gavage | 10 mg/kg | Once daily, 5 consecutive days/week | PLX51107 and PLX2853 showed significant therapeutic effects in wild-type Em-myc lymphoma models but limited efficacy in BCL-2-high models. Combination with the BH3 mimetic ABT199 significantly enhanced tumor control. | PMC7391160 |
DBA mice | Collagen-induced arthritis model | Oral gavage | 10 mg/kg | Three times per week for 5 weeks | To evaluate the effect of PLX51107 on FcγR expression and arthritis symptoms in vivo. Results showed that PLX51107 significantly reduced footpad swelling and downregulated FcγR expression in monocytes and macrophages in the spleen. | PMC10143512 |
Mice | BrafV600E, Ptennull, Cdkn2dnul1 YUMM1.7 tumor model | Oral | 557-1500 ng/ml | 12 days | PLX51107 significantly delayed melanoma growth, reduced the frequency of tumor-infiltrating Tregs, increased the CD8/Tregs ratio, and decreased PD1 expression on CD8+ T cells. Combined with anti-PD-L1, it significantly inhibited tumor growth. | PMC6591077 |
Nude mice | Xenograft model | Oral | 24 mg/kg/day | Once daily for 24 days or 48 days | Evaluate the inhibitory effect of PLX on tumor growth, results showed that PLX significantly inhibited the growth of xenograft tumors. | PMC6938575 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT02683395 | Solid Tumors|Acute Myeloid Leu... More >>kemia|Myelodysplastic Syndrome|Non-Hodgkin's Lymphoma Less << | PHASE1 | TERMINATED | 2025-09-18 | Columbia University Medical Ce... More >>nter, New York, New York, 10032, United States|The Ohio State University Stephanie Spielman Comprehensive Breast Center, Columbus, Ohio, 43212, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, 19107, United States|MUSC/ Hollings Cancer Center, Charleston, South Carolina, 29425, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, 78229, United States Less << |
Tags: PLX51107 | PLX 51107 | PLX-51107 | Epigenetic Reader Domain | Bromodomain and Extra-Terminal | BET inhibitor | BRD2 inhibitor | BRD3 inhibitor | BRD4 inhibitor | BRDT inhibitor | bromodomain | 1627929-55-8
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL